Delta Air Lines (DAL) - FREE Research Report

Carp Daniel A who is Director at Delta Air Lines sold 11,010 shares at $27.31 on Nov. 7, 2013. Following this transaction, the Director owned 49,263 shares meaning that the stake was reduced by 18.27% with the 11,010 share transaction.

The shares most recently traded at $27.50, up $0.19, or 0.69% since the insider transaction. Historical insider transactions for Delta Air Lines go as follows:

  • 4-Week # shares bought: 4,000
  • 4-Week # shares sold: 345,043
  • 12-Week # shares bought: 19,000
  • 12-Week # shares sold: 384,339
  • 24-Week # shares bought: 24,000
  • 24-Week # shares sold: 525,517

The average volume for Delta Air Lines has been 18.7 million shares per day over the past 30 days. Delta Air Lines has a market cap of $23.0 billion and is part of the services sector and transportation industry. Shares are up 126.45% year to date as of the close of trading on Thursday.

Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. Its route network is centered around a system of hub and international gateway airports in Amsterdam, Atlanta, Cincinnati, Detroit, Memphis, Minneapolis-St. The stock currently has a dividend yield of 0.89%. The company has a P/E ratio of 11.2. Currently there are 7 analysts that rate Delta Air Lines a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DAL - FREE

TheStreet Quant Ratings rates Delta Air Lines as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, solid stock price performance, impressive record of earnings per share growth and revenue growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Delta Air Lines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts